Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trifluridine/Tipiracil in Colorectal/Oesogastric Cancer After Fluoropyrimidine Cardiotoxicity
NCT04894123Phase 2Terminated
- Sponsor
- GERCOR
- Start
- Feb 2022
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of trifluridine + tipiracil in colorectal adenocarcinoma, Gastroesophageal junction adenocarcinoma (GEJA), sponsored by GERCOR. Started Feb 2022; status: terminated.
02
Drugs
trifluridine + tipiracil
03
Conditions
colorectal adenocarcinomaGastroesophageal junction adenocarcinoma (GEJA)
Beyond the preview
Go deeper on NCT04894123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04894123.